147 related articles for article (PubMed ID: 32968863)
21. LI-RADS version 2018 treatment response algorithm on extracellular contrast-enhanced MRI in patients treated with transarterial chemoembolization for hepatocellular carcinoma: diagnostic performance and the added value of ancillary features.
Wang D; Zhang Y; Lyu R; Jia K; Xu PJ
Abdom Radiol (NY); 2024 Apr; ():. PubMed ID: 38605217
[TBL] [Abstract][Full Text] [Related]
22. Validation of the Liver Imaging Reporting and Data System Treatment Response Criteria After Thermal Ablation for Hepatocellular Carcinoma.
Cools KS; Moon AM; Burke LMB; McGinty KA; Strassle PD; Gerber DA
Liver Transpl; 2020 Feb; 26(2):203-214. PubMed ID: 31677319
[TBL] [Abstract][Full Text] [Related]
23. LI-RADS Treatment Response Algorithm: Performance and Diagnostic Accuracy With Radiologic-Pathologic Explant Correlation in Patients With SBRT-Treated Hepatocellular Carcinoma.
Mendiratta-Lala M; Aslam A; Maturen KE; Westerhoff M; Maurino C; Parikh ND; Sun Y; Sonnenday CJ; Stein EB; Shampain KL; Kaza RK; Cuneo K; Masch W; Do RKG; Lawrence TS; Owen D
Int J Radiat Oncol Biol Phys; 2022 Mar; 112(3):704-714. PubMed ID: 34644607
[TBL] [Abstract][Full Text] [Related]
24. Performance of initial LI-RADS 2018 treatment response in predicting survival of patients with hepatocellular carcinoma following TACE: a retrospective, single-center cohort study.
Bartnik K; Podgórska J; Rosiak G; Korzeniowski K; Giziński J; Sajdek M; Wróblewski T; Zieniewicz K; Nyckowski P; Rowiński O
J Cancer Res Clin Oncol; 2021 Dec; 147(12):3673-3683. PubMed ID: 33778924
[TBL] [Abstract][Full Text] [Related]
25. Performance of LI-RADS Version 2018 on CT for Determining Eligibility for Liver Transplant According to Milan Criteria in Patients at High Risk for Hepatocellular Carcinoma.
Bae JS; Lee DH; Lee SM; Suh KS; Lee KW; Yi NJ; Lee KB; Kim H; Han JK
AJR Am J Roentgenol; 2022 Jul; 219(1):86-96. PubMed ID: 35138137
[No Abstract] [Full Text] [Related]
26. Abbreviated MRI Protocol for the Assessment of Ablated Area in HCC Patients.
Granata V; Grassi R; Fusco R; Setola SV; Belli A; Piccirillo M; Pradella S; Giordano M; Cappabianca S; Brunese L; Grassi R; Petrillo A; Izzo F
Int J Environ Res Public Health; 2021 Mar; 18(7):. PubMed ID: 33808466
[TBL] [Abstract][Full Text] [Related]
27. Diagnostic accuracy of contrast-enhanced ultrasound for the differential diagnosis of hepatocellular carcinoma: ESCULAP versus CEUS-LI-RADS.
Schellhaas B; Görtz RS; Pfeifer L; Kielisch C; Neurath MF; Strobel D
Eur J Gastroenterol Hepatol; 2017 Sep; 29(9):1036-1044. PubMed ID: 28562394
[TBL] [Abstract][Full Text] [Related]
28. Combined hepatocellular-cholangiocarcinoma: can we use contrast-enhanced ultrasound Liver Imaging Reporting and Data System (LI-RADS) to predict the patient's survival?
Yang J; Huang JY; Chen X; Ling WW; Luo Y; Shi YJ; Liu JB; Lu Q; Lyshchik A
Eur Radiol; 2021 Aug; 31(8):6397-6405. PubMed ID: 33492470
[TBL] [Abstract][Full Text] [Related]
29. Accuracy of the Liver Imaging Reporting and Data System in Computed Tomography and Magnetic Resonance Image Analysis of Hepatocellular Carcinoma or Overall Malignancy-A Systematic Review.
van der Pol CB; Lim CS; Sirlin CB; McGrath TA; Salameh JP; Bashir MR; Tang A; Singal AG; Costa AF; Fowler K; McInnes MDF
Gastroenterology; 2019 Mar; 156(4):976-986. PubMed ID: 30445016
[TBL] [Abstract][Full Text] [Related]
30. Locoregional therapies for hepatocellular carcinoma and the new LI-RADS treatment response algorithm.
Kielar A; Fowler KJ; Lewis S; Yaghmai V; Miller FH; Yarmohammadi H; Kim C; Chernyak V; Yokoo T; Meyer J; Newton I; Do RK
Abdom Radiol (NY); 2018 Jan; 43(1):218-230. PubMed ID: 28780679
[TBL] [Abstract][Full Text] [Related]
31. Progression Rates of LR-2 and LR-3 Observations on MRI to Higher LI-RADS Categories in Patients at High Risk of Hepatocellular Carcinoma: A Retrospective Study.
Ranathunga D; Osman H; Islam N; McInnes MDF; Munir J; van der Pol CB; Elfaal M; Walsh C
AJR Am J Roentgenol; 2022 Mar; 218(3):462-470. PubMed ID: 34643108
[No Abstract] [Full Text] [Related]
32. A retrospective single-centre analysis of the oncological impact of LI-RADS classification applied to Metroticket 2.0 calculator in liver transplantation: every nodule matters.
Centonze L; Di Sandro S; Lauterio A; De Carlis R; Sgrazzutti C; Ciulli C; Vella I; Vicentin I; Incarbone N; Bagnardi V; Vanzulli A; De Carlis L
Transpl Int; 2021 Sep; 34(9):1712-1721. PubMed ID: 34448275
[TBL] [Abstract][Full Text] [Related]
33. Assessment of hepatocellular carcinoma treatment response with LI-RADS: a pictorial review.
Voizard N; Cerny M; Assad A; Billiard JS; Olivié D; Perreault P; Kielar A; Do RKG; Yokoo T; Sirlin CB; Tang A
Insights Imaging; 2019 Dec; 10(1):121. PubMed ID: 31853668
[TBL] [Abstract][Full Text] [Related]
34. Diagnostic Performance of LI-RADS Version 2018 for Evaluation of Pediatric Hepatocellular Carcinoma.
Khanna G; Chavhan GB; Schooler GR; Fraum TJ; Alazraki AL; Squires JH; Salter A; Podberesky DJ; Towbin AJ
Radiology; 2021 Apr; 299(1):190-199. PubMed ID: 33620289
[TBL] [Abstract][Full Text] [Related]
35. CT and MRI Liver Imaging Reporting and Data System Version 2018 for Hepatocellular Carcinoma: A Systematic Review With Meta-Analysis.
Lee S; Kim YY; Shin J; Hwang SH; Roh YH; Chung YE; Choi JY
J Am Coll Radiol; 2020 Oct; 17(10):1199-1206. PubMed ID: 32640250
[TBL] [Abstract][Full Text] [Related]
36. Diagnostic Accuracy of CEUS LI-RADS for the Characterization of Liver Nodules 20 mm or Smaller in Patients at Risk for Hepatocellular Carcinoma.
Huang JY; Li JW; Lu Q; Luo Y; Lin L; Shi YJ; Li T; Liu JB; Lyshchik A
Radiology; 2020 Feb; 294(2):329-339. PubMed ID: 31793849
[TBL] [Abstract][Full Text] [Related]
37. Intraindividual Comparison of Contrast-Enhanced Ultrasound Using Perfluorobutane With Modified Criteria Versus CT/MRI LI-RADS Version 2018 for Diagnosing HCC in High-Risk Patients.
Li L; Mao S; Wang J; Zheng W; Shen J; Clevert DA; Zhou J
AJR Am J Roentgenol; 2023 May; 220(5):682-691. PubMed ID: 36382914
[No Abstract] [Full Text] [Related]
38. Assessment of primary liver carcinomas other than hepatocellular carcinoma (HCC) with LI-RADS v2018: comparison of the LI-RADS target population to patients without LI-RADS-defined HCC risk factors.
Fraum TJ; Cannella R; Ludwig DR; Tsai R; Naeem M; LeBlanc M; Salter A; Tsung A; Shetty AS; Borhani AA; Furlan A; Fowler KJ
Eur Radiol; 2020 Feb; 30(2):996-1007. PubMed ID: 31654212
[TBL] [Abstract][Full Text] [Related]
39. Does Training in LI-RADS Version 2018 Improve Readers' Agreement with the Expert Consensus and Inter-reader Agreement in MRI Interpretation?
Zhang N; Xu H; Ren AH; Zhang Q; Yang DW; Ba T; Wang ZC; Yang ZH
J Magn Reson Imaging; 2021 Dec; 54(6):1922-1934. PubMed ID: 33963801
[TBL] [Abstract][Full Text] [Related]
40. A radiogenomic analysis of hepatocellular carcinoma: association between fractional allelic imbalance rate index and the liver imaging reporting and data system (LI-RADS) categories and features.
Furlan A; Almusa O; Yu RK; Sagreiya H; Borhani AA; Bae KT; Marsh JW
Br J Radiol; 2018 Jun; 91(1086):20170962. PubMed ID: 29565672
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
